Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors.
Taieb J, Ambrosini M, Alouani E, Lonardi S, Sinicrope FA, Decraecker M, Boileve A, Hafliger E, Mazard T, Pernot S, Parent P, Ros J, Overman MJ, Jayachandran P, Nasca V, Salvatore L, Guimbaud R, Cremolini C, Tougeron D, Pietrantonio F. Taieb J, et al. Among authors: nasca v. J Immunother Cancer. 2025 Jan 4;13(1):e010424. doi: 10.1136/jitc-2024-010424. J Immunother Cancer. 2025. PMID: 39755579 Free article.
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.
Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A. Urtecho SB, et al. Among authors: nasca v. Lung Cancer. 2024 Dec 9;199:108051. doi: 10.1016/j.lungcan.2024.108051. Online ahead of print. Lung Cancer. 2024. PMID: 39740426
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon.
Pretta A, Ziranu P, Perissinotto E, Ghelardi F, Marmorino F, Giampieri R, Puci M, De Grandis MC, Lai E, Nasca V, Ciraci P, Puzzoni M, Cerma K, Sciortino C, Taravella A, Pretta G, Giuliani L, Damonte C, Pusceddu V, Sotgiu G, Berardi R, Lonardi S, Bergamo F, Pietrantonio F, Cremolini C, Scartozzi M. Pretta A, et al. Among authors: nasca v. Br J Cancer. 2024 Nov 27. doi: 10.1038/s41416-024-02902-5. Online ahead of print. Br J Cancer. 2024. PMID: 39604610
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.
Moretto R, Rossini D, Murgioni S, Ciracì P, Nasca V, Germani MM, Calegari MA, Vetere G, Intini R, Taravella A, Studiale V, Boccaccio C, Passardi A, Tamburini E, Zaniboni A, Salvatore L, Pietrantonio F, Lonardi S, Masi G, Cremolini C. Moretto R, et al. Among authors: nasca v. JCO Precis Oncol. 2024 Nov;8:e2400329. doi: 10.1200/PO.24.00329. Epub 2024 Nov 7. JCO Precis Oncol. 2024. PMID: 39509668
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden.
Provenzano L, Gwee YX, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao JJ, Chia DKA, Yong WP, Tan P, So J, Kim G, Shabbir A, Ong CJ, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Provenzano L, et al. Among authors: nasca v. Ther Adv Med Oncol. 2024 Nov 4;16:17588359241289517. doi: 10.1177/17588359241289517. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39502404 Free PMC article.
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, Conca E, Capone I, Busico A, Perrone F, Tamborini E, Sabella G, Greco G, Greco FG, Tafuto S, Procopio G, Morano F, Niger M, Maccauro M, Milione M, de Braud F, Pietrantonio F, Pusceddu S. Nasca V, et al. Eur J Cancer. 2024 Sep;209:114276. doi: 10.1016/j.ejca.2024.114276. Epub 2024 Aug 9. Eur J Cancer. 2024. PMID: 39128186 Clinical Trial.
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors.
Ghelardi F, Fucà G, Cavalli C, Shitara K, Cohen R, Ambrosini M, Maron SB, Cerantola R, Nasca V, Liberti GD, Zambelli L, Palazzo M, Salati M, Aoki Y, Kawazoe A, Cowzer D, Lonardi S, André T, Randon G, Pietrantonio F. Ghelardi F, et al. Among authors: nasca v. Dig Liver Dis. 2025 Jan;57(1):23-29. doi: 10.1016/j.dld.2024.05.005. Epub 2024 May 21. Dig Liver Dis. 2025. PMID: 38772790 Free article.
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
Fanotto V, Rossini D, Casagrande M, Bergamo F, Spagnoletti A, Santini D, Antoniotti C, Cupini S, Daniel F, Nasca V, Vetere G, Zaniboni A, Borelli B, Carullo M, Conca V, Passardi A, Tamburini E, Masi G, Pella N, Cremolini C. Fanotto V, et al. Among authors: nasca v. Cancers (Basel). 2023 Nov 16;15(22):5451. doi: 10.3390/cancers15225451. Cancers (Basel). 2023. PMID: 38001711 Free PMC article.
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
Ghelardi F, Raimondi A, Morano F, Randon G, Pannone A, Guaglio M, Mazzoli G, Nasca V, Milione M, Leoncini G, Sabella G, Greco GF, Lampis BR, Galassi M, Delfanti S, Nannini M, Intini R, Baratti D, Di Bartolomeo M, Deraco M, Pietrantonio F. Ghelardi F, et al. Among authors: nasca v. Clin Colorectal Cancer. 2023 Dec;22(4):450-456.e1. doi: 10.1016/j.clcc.2023.08.005. Epub 2023 Aug 11. Clin Colorectal Cancer. 2023. PMID: 37657955
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
Ligorio F, Lobefaro R, Fucà G, Provenzano L, Zanenga L, Nasca V, Sposetti C, Salvadori G, Ficchì A, Franza A, Martinetti A, Sottotetti E, Formisano B, Depretto C, Scaperrotta G, Belfiore A, Vingiani A, Ferraris C, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: nasca v. Int J Cancer. 2024 Jan 1;154(1):114-123. doi: 10.1002/ijc.34701. Epub 2023 Aug 24. Int J Cancer. 2024. PMID: 37615485 Free article.
16 results